Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last4,881 to 4,900 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Palbociclib vs Placebo: serious adverse events | 64 of 633 65 of 611 | -0.5 points -4.0 to 2.9 | 1,244 | NCT01864746 A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery |
| Nadroparin vs Fondaparinux: Number of Participants With Confirmed VTE and Death up to the Final Visit or Contact | 49 of 622 15 of 621 | 5.5 points 3.0 to 8.0 | 1,243 | NCT00843492 A Study to Evaluate the Efficacy and Safety of Fondaparinux for the Prevention of Venous Blood Clots in Patients With a Plaster Cast or Other Type of Immobilization for a Below-knee Injury Not Needing Surgery |
| Multilevel Intervention vs Control: deaths from any cause | 5 of 627 4 of 614 | 0.1 points -1.0 to 1.3 | 1,241 | NCT03683173 Promoting Physical Activity in Rural Communities |
| Vandetanib vs Erlotinib: Objective Response Rate (ORR) | 75 of 623 74 of 617 | 0.0 points -3.6 to 3.7 | 1,240 | NCT00364351 Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy |
| Vandetanib vs Erlotinib: Disease Control Rate (DCR) | 254 of 623 242 of 617 | 1.5 points -3.9 to 7.0 | 1,240 | NCT00364351 Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy |
| Left Atrial Ablation vs Rate or Rhythm Control Therapy: Number of Participants Free From Recurrent Atrial Fibrillation (AF) Following the 90 Day Blanking Period | 305 of 611 437 of 629 | -19.6 points -24.8 to -14.1 | 1,240 | NCT00911508 Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial |
| Naldemedine vs Placebo: serious adverse events | 60 of 621 73 of 619 | -2.1 points -5.6 to 1.3 | 1,240 | NCT01965652 Long Term Safety of Naldemedine |
| Vandetanib vs Erlotinib: serious adverse events | 197 of 623 155 of 614 | 6.4 points 1.3 to 11.4 | 1,237 | NCT00364351 Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy |
| Best Practice Clinic-Based Care vs Telehealth Care: Number of Participants Identifying Cost of Care or Medications as BP Care Burden at Six Months | 188 of 649 134 of 588 | 6.2 points 1.3 to 11.0 | 1,237 | NCT02996565 Pragmatic Trial Comparing Telehealth Care and Optimized Clinic-Based Care for Uncontrolled High Blood Pressure |
| PREP (Potentially Reduced Exposure Product) Group vs Cigarette Group: serious adverse events | 3 of 626 3 of 610 | -0.0 points -1.0 to 1.0 | 1,236 | NCT01509586 A Test of Short and Long Term Naturalistic Outcomes of Smokers Who Sample Smokeless Tobacco |
| Motavizumab (MEDI-524) vs Palivizumab: The Number of Subjects Hospitalized for RSV Infection. | 12 of 623 16 of 612 | -0.7 points -2.5 to 1.0 | 1,235 | NCT00538785 A Study to Evaluate MEDI-524 In Children With Hemodynamically Significant Congenital Heart Disease |
| Pembrolizumab + Enzalutamide vs Placebo + Enzalutamide: Number of Participants Who Discontinue Study Treatment Due to an Adverse Event (AE) | 115 of 615 50 of 620 | 10.6 points 6.9 to 14.4 | 1,235 | NCT03834493 Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641) |
| Pembrolizumab + Enzalutamide vs Placebo + Enzalutamide: Number of Participants Who Experience an Adverse Event (AE) | 594 of 615 596 of 620 | 0.5 points -1.7 to 2.6 | 1,235 | NCT03834493 Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641) |
| Q/LAIV (MEDI3250) vs FluMist/B/Yamagata: The Number of Seropositive Participants Within Each Treatment Arm Who Experience B/Yamagata Strain-specific Seroresponse Post Dose. | 52 of 983 13 of 249 | 0.1 points -3.6 to 2.7 | 1,232 | NCT00860067 A Study to Evaluate the Immunogenicity of Quadrivalent LAIV in Adults 18 to 49 Years of Age |
| Q/LAIV (MEDI3250) vs FluMist/B/Yamagata: The Number of Seropositive Participants Within Each Treatment Arm Who Achieved a B/Yamagata Strain-specific HAI Antibody Titer ≥ 32 Post Dose. | 837 of 983 215 of 249 | -1.2 points -5.6 to 4.1 | 1,232 | NCT00860067 A Study to Evaluate the Immunogenicity of Quadrivalent LAIV in Adults 18 to 49 Years of Age |
| Without Hepatic Dysfunction vs With Hepatic Dysfunction: Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Hepatic Dysfunction. | 14 of 1,087 2 of 145 | -0.1 points -3.6 to 1.2 | 1,232 | NCT01107743 Amlodipine/Atorvastatin (Caduet®) Drug Use Investigation (Regulatory Post Marketing Commitment Plan) |
| EEG Guided Protocol vs Control Arm: deaths from any cause | 4 of 614 20 of 618 | -2.6 points -4.3 to -1.1 | 1,232 | NCT02241655 Electroencephalography Guidance of Anesthesia |
| EEG Guided Protocol vs Control Arm: serious adverse events | 124 of 614 130 of 618 | -0.8 points -5.4 to 3.7 | 1,232 | NCT02241655 Electroencephalography Guidance of Anesthesia |
| Napabucasin + FOLFIRI ± Bevacizumab vs FOLFIRI ± Bevacizumab: serious adverse events | 234 of 622 201 of 610 | 4.7 points -0.7 to 10.0 | 1,232 | NCT02753127 A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer |
| Without Renal Dysfunction vs With Renal Dysfunction: Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Renal Dysfunction. | 14 of 1,123 2 of 108 | -0.6 points -5.3 to 1.0 | 1,231 | NCT01107743 Amlodipine/Atorvastatin (Caduet®) Drug Use Investigation (Regulatory Post Marketing Commitment Plan) |
Code
curl "https://conductscience.org/api/comparisons/v1?page=245"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=245
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT01864746-sae",
"title": "Palbociclib vs Placebo: serious adverse events",
"summary": "64 of 633 against 65 of 611; risk difference -0.5 points, 95% interval -4.0 to 2.9; NCT01864746, A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery",
"record": "/library/comparisons/NCT01864746-sae",
"nct_id": "NCT01864746",
"kind": "serious-adverse-events",
"participants": 1244,
"risk_difference": {
"value": -0.005277133541729692,
"lower": -0.0395270897918196,
"upper": 0.02876161055165794
},
"group_1": "64 of 633",
"group_2": "65 of 611",
"difference": "-0.5 points",
"interval": "-4.0 to 2.9",
"trial_title": "A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery"
},
{
"id": "NCT00843492-2bf69023",
"title": "Nadroparin vs Fondaparinux: Number of Participants With Confirmed VTE and Death up to the Final Visit or Contact",
"summary": "49 of 622 against 15 of 621; risk difference 5.5 points, 95% interval 3.0 to 8.0; NCT00843492, A Study to Evaluate the Efficacy and Safety of Fondaparinux for the Prevention of Venous Blood Clots in Patients With a Plaster Cast or Other Type of Immobilization for a Below-knee Injury Not Needing Surgery",
"record": "/library/comparisons/NCT00843492-2bf69023",
"nct_id": "NCT00843492",
"kind": "outcome",
"participants": 1243,
"risk_difference": {
"value": 0.05462354567625084,
"lower": 0.03047025552051431,
"upper": 0.0802813345694991
},
"group_1": "49 of 622",
"group_2": "15 of 621",
"difference": "5.5 points",
"interval": "3.0 to 8.0",
"trial_title": "A Study to Evaluate the Efficacy and Safety of Fondaparinux for the Prevention of Venous Blood Clots in Patients With a Plaster Cast or Other Type of Immobilization for a Below-knee Injury Not Needing Surgery"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=246",
"request_id": "7RMo5FEWy1qnjKQA"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
The conductscience.com catalog
One instrument from the ConductScience store with the tests, measures and species it is used for, the papers that used it, and the MeSH topics of those papers.
Open Targets
One drug with its targets, the diseases it is studied for, and the trials that name it, with their comparisons, papers and cognitive tests.
Open Targets
One disease with the drugs studied for it, the targets those drugs act on, and the trials that study it, with their comparisons and papers.
ClinicalTrials.gov
One company with the trials it leads or helps run, the drugs those trials test, the conditions they study and the organizations it runs them with.
Cellosaurus
One cell line with the problems Cellosaurus records for it, its relatives, the cell banks that hold it, and the papers that used it.
PubMed and NLM's journal list
One journal with its papers in PubMed since 1959, year by year, its retracted papers, errata and expressions of concern, and how many of its papers have a copy in PMC.
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant